Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Nephros, Inc. (OTC: NEPH).

Full DD Report for NEPH

You must become a subscriber to view this report.


Recent News from (OTC: NEPH)

Specialty Renal Products Announces $3 Million Series A Financing
SOUTH ORANGE, NJ, Sept. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Specialty Renal Products, Inc. (SRP), a private medical device company focused on the development of products for patients with renal disease, including a hemodiafiltration (HDF) system for the treatment of patients wi...
Source: GlobeNewswire
Date: September, 06 2018 07:30
Nephros: HemoCleanse Partnership To Deliver Further Upside
Nephros (OTC: OTCQB:NEPH ) is a highly promising company operating near its growth inflection. There are multiple catalysts powering organic growth. First, the company posted eight consecutive quarters of increasing revenues. And, we expect the trend to continue going forward. Second, the SRP ...
Source: SeekingAlpha
Date: September, 05 2018 12:05
Nephros in-licenses technology for filtration system for treatment of renal disease
Nephros ( OTCQB:NEPH ) subsidiary Specialty Renal Products (SRP) inks an agreement with HemoCleanse Technologies for the global development and commercialization rights to a dialysate regeneration and filtration system for the treatment of renal disease. More news on: Nephros, Inc., Heal...
Source: SeekingAlpha
Date: August, 14 2018 07:54
Nephros Subsidiary Specialty Renal Products and HemoCleanse Announce License Agreement for Dialysate Filtration System
Pioneering HemoCleanse CEO to Join Specialty Renal Products Board of Directors SOUTH ORANGE, NJ, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Specialty Renal Products, Inc. (SRP), a subsidiary of Nephros, Inc. (OTCQB:NEPH), a medical device company that develops and sells a hemodiafiltration syste...
Source: GlobeNewswire
Date: August, 14 2018 07:30
Nephros Appoints Oliver Spandow to its Board of Directors
Seasoned Executive Adds Significant Operational and M&A Expertise SOUTH ORANGE, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters announced today ...
Source: GlobeNewswire
Date: August, 13 2018 07:30
Nephros, Inc. (NEPH) CEO Daron Evans on Q2 2018 Results - Earnings Call Transcript
Nephros, Inc. (NEPH) Q2 2018 Results Earnings Conference Call August 8, 2018, 04:30 PM ET Executives Kirin Smith - PCG Advisory Group Daron Evans - CEO Andy Astor - CFO Analysts Peter Kozlowski - Windward Venture Partners Arthur Winston - Pilot Advisors Gary Sacks - RHK...
Source: SeekingAlpha
Date: August, 12 2018 11:11
Nephros Reports Second Quarter 2018 Financial Results
Quarterly Product Revenue Up 55% Year-over-Year; Total Revenue Up 59% Company Plans Uplist to National Stock Exchange Conference Call Scheduled for Today, August 8, 2018, at 4:30 PM EDT SOUTH ORANGE, N.J., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH) (“N...
Source: GlobeNewswire
Date: August, 08 2018 16:10
Nephros Schedules Second Quarter Financial Results Conference Call
Call scheduled for Wednesday, August 8 th at 4:30 PM EDT SOUTH ORANGE, NJ, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hem...
Source: GlobeNewswire
Date: August, 03 2018 08:00
Rounds Report: Nephros Posts Strong Preliminary Financial Results For Q2
There’s no better tip-off to the probable success of a stock than that people in the company are putting their money into it. In general, corporate insiders are net sellers, and they normally sell 2.3 shares to every one share that they buy. After the 1,000-point drop from August to...
Source: SeekingAlpha
Date: July, 13 2018 09:48
Nephros announces preliminary Q2 results
Nephros ( OTCQB:NEPH ) expects total revenue to be ~$1.35M (~+57% Y/Y). More news on: Nephros, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 09 2018 09:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.6750.67450.67750.674511,123
2018-12-070.680.6750.680.67534,068
2018-12-060.670.680.700.6715,639
2018-12-050.690.690.690.6728,688
2018-12-040.690.690.690.6728,688

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-102,00011,12317.9808Cover
2018-12-073,00034,0688.8059Cover
2018-12-0613,51615,63986.4250Short
2018-12-042,66228,6889.2791Cover
2018-12-036,32214,58043.3608Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NEPH.


About Nephros, Inc. (OTC: NEPH)

Logo for Nephros, Inc. (OTC: NEPH)

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria i.e. Legionella, Pseudomonas , virus and endotoxin from water used by patients. For more information about Nephros, please visit the company s website at www.nephros.com

 

Contact Information

 

 

Current Management

  • Daron Evans / President, CEO
  • Andrew Astor / CFO
    • Andrew Astor is a technology and business executive with years of financial and operating experience. Mr. Astor was most recently President and Chief Financial Officer at Open Source Consulting Group, a growth stage services firm. Previously, he was a Managing Director at Synechron, a global consulting organization, from to . From to , he served as Vice President at Asurion, a large, privately held insurance company. Mr. Astor was cofounder of the software company EnterpriseDB, and served as its CEO from to . Mr. Astor was Vice President, Strategic Solutions at webMethods ETR: SOW , a software firm, from to . Mr. Astor was Vice President of Transactional Products at Dun amp Bradstreet NYSE: DNB from to . Prior to , Mr. Astor held various roles at American Management Systems, SHL/MCI Systemhouse, and Ernst amp Young. Mr. Astor received his Bachelor of Arts in Mathematics from Clark University, and his MBA from The Wharton School at the University of Pennsylvania.
  • Arthur Amron /
  • Paul Mieyal / Audit Committee Member
  • Malcom Persen / Independent Director, Audit Committee Member
  • Moshe Pinto / Independent Director
    • Mr. Pinto was recently the CEO of Home Dialysis Plus, now Outset Medical, Inc., a Warburg Pincus backed company dedicated to the development and commercialization of a new hemodialysis system, providing an improved experience for patients. Previously, from through , he was CEO of Spiracur Inc., a developer of innovative wound healing technologies that Mr. Pinto cofounded out of the Stanford University Biodesign Innovation Program. Mr. Pinto also worked for Herzog, Fox amp Neeman, a law firm based in Israel. He currently serves on the Board of Directors of Spiracur Inc. Mr. Pinto received an MBA from Stanford University, an LLM from Universita di Bologna, an EMLE from the University of Hamburg, and an LLB in Law from Tel Aviv University.

Current Share Structure

  • Market Cap: $25,601,970 - 03/16/2018
  • Authorized: 90,000,000 - 03/01/2018
  • Issue and Outstanding: 56,893,266 - 03/01/2018
  • Float: 22,750,000 - 06/01/2017

 


Recent Filings from (OTC: NEPH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 09 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 18 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 11 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 11 2018

 

 


Daily Technical Chart for (OTC: NEPH)

Daily Technical Chart for (OTC: NEPH)


Stay tuned for daily updates and more on (OTC: NEPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NEPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NEPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NEPH and does not buy, sell, or trade any shares of NEPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/